Clinical GuidelineGuidelineMedication SafetyPatient Education

Pregnancy nicotine guideline recommends routine screening and behavioral counseling

Journal of Obstetrics and Gynaecology Canada (PubMed)Aug 3, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A Society of Obstetricians and Gynaecologists of Canada guideline recommends routine nicotine-use screening in pregnancy, behavioral counseling as first-line support, cautious pharmacotherapy when needed, and continued postpartum relapse prevention.

What NurseJet pulled from the source

Guideline No. 470 addresses combustible tobacco, electronic cigarettes, and smokeless tobacco for people who are pregnant or planning pregnancy. It used literature reviews and GRADE to cover screening, counseling, nicotine-replacement and other pharmacotherapy, harm reduction, system interventions, and postpartum follow-up.

Why this matters for nurses

Obstetric nurses and nurse practitioners often have repeated opportunities to ask about nicotine without judgment, offer cessation support, and connect patients with follow-up. The guideline frames this as ongoing prenatal and postpartum care rather than a one-time warning.

Bedside takeaway

Ask about every nicotine product, pair screening with supportive counseling, and plan follow-up through the postpartum period.

How This Applies in Practice

Use this when: Screening or counseling a patient who is pregnant, planning pregnancy, or postpartum about cigarettes, vaping, or other nicotine products.

On your shift

Ask privately and nonjudgmentally about each nicotine product, frequency, recent use, prior quit attempts, and readiness for support.
Offer the approved behavioral counseling and cessation-referral pathway and document the agreed follow-up plan.
Verify prescriber review and the individualized order before teaching about nicotine replacement or other pharmacotherapy.

Keep in mind: The abstract does not contain the full graded recommendations, and Canadian guidance may not match local requirements. Follow the obstetric protocol, facility policy, and provider orders.

Key takeaways

The guideline covers all nicotine-containing products, including cigarettes, e-cigarettes, and smokeless tobacco.
Routine screening and behavioral counseling are recommended as first-line care.
Nicotine-replacement or other pharmacotherapy should be considered cautiously when needed.
Support should continue postpartum because relapse prevention remains part of nicotine care.

Practice implications

Use a private, nonjudgmental screen that includes cigarettes, vaping, and smokeless products. Document use and readiness, offer the approved counseling and referral pathway, and verify that any nicotine-replacement or other medication plan has been individualized and ordered.

Limitations & cautions

The PubMed abstract summarizes the guideline's scope and overall recommendations but does not reproduce its recommendation tables, evidence grades, contraindications, or medication details. Local practice may differ from Canadian guidance, so clinicians must review the complete guideline and applicable policy.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Journal of Obstetrics and Gynaecology Canada (PubMed)

Journal of Obstetrics and Gynaecology Canada (PubMed). Guideline No. 470: Nicotine and Pregnancy.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42547374/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Renal failure (PubMed)Sep 7, 2026Research Article

A single-center retrospective cohort found that approximately one quarter of laboratory-defined acute kidney injury cases on internal medicine wards were not documented, particularly when maximal creatinine was lower.

Med-SurgAI summaryReview source

Research ArticleResearchQuality ImprovementAI summary · original source linked below

Among 161 adult hospitalizations meeting serum-creatinine criteria for acute kidney injury, 39 cases (24.2%) were undocumented. Length of stay and in-hospital mortality did not differ significantly by documentation status.

Key takeaways

In the 149 hospitalizations with a demonstrable creatinine change, 33 cases (22.1%) were undocumented.
Higher maximal creatinine was associated with lower adjusted odds of underdocumentation.
The study did not test whether a detection or documentation intervention improves care or outcomes.

Why this matters on shift

A smaller creatinine rise may receive less attention even when it meets the study's laboratory definition of acute kidney injury, which can affect how renal risk is communicated across the inpatient team.

Bedside takeaway

Trend ordered renal-function results and communicate clinically important changes through local escalation and documentation workflows.

Nursing implications

Trend ordered renal-function results and communicate clinically important changes through the care team according to local escalation and documentation workflows.

Limitations & cautions

Abstract-only summary. This was a retrospective, single-center study of 161 hospitalizations; urine-output criteria and reliable preadmission creatinine values were unavailable, and the reference creatinine method may affect case classification.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Renal failure (PubMed). Underdocumentation of laboratory-defined acute kidney injury in internal medicine wards: a retrospective cohort study.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of midwifery & women's health (PubMed)Sep 7, 2026Research Article

A retrospective analysis of US natality data found no statistically significant yearly difference in neonatal mortality between freestanding birth centers and hospitals among term, singleton, vertex births without major medical risk factors from 2015 through 2024.

L&D / OB PedsAI summaryReview source

Research ArticleResearchPatient EducationAI summary · original source linked below

Adjusted neonatal-mortality odds for freestanding birth centers fluctuated around 1.0 across the 10-year study period. No individual year showed a statistically significant difference from hospital births, including 2020 and 2021 when birth-center volume increased.

Key takeaways

The analysis was restricted to births meeting selected low-risk criteria.
The study found no evidence that higher birth-center use during the pandemic years increased neonatal mortality.
The observational design cannot establish that birth setting itself caused the mortality pattern.

Why this matters on shift

The findings add national outcome data for counseling and systems planning around freestanding birth-center care for appropriately selected low-risk pregnancies.

Bedside takeaway

Apply local eligibility, surveillance, escalation, and transfer protocols when caring for planned low-risk birth-center patients.

Nursing implications

Keep eligibility, surveillance, escalation, and transfer decisions anchored to local birth-center criteria and maternal-newborn protocols.

Limitations & cautions

Abstract-only summary. The study used retrospective vital-record data, was limited to selected low-risk births, and cannot exclude residual differences between people who delivered in birth centers and hospitals.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of midwifery & women's health (PubMed). Neonatal Mortality Risk Among Births in Freestanding Birth Centers, 2015 to 2024.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

European heart journal (PubMed)Sep 6, 2026Research Article

In the pragmatic TARGET-D randomized trial, vitamin D dosing titrated to a serum target did not significantly reduce the composite of death, recurrent myocardial infarction, heart-failure hospitalization, or stroke after myocardial infarction.

Telemetry Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyPatient EducationAI summary · original source linked below

Among 630 participants followed for an average of 4.2 years, major cardiovascular events occurred in 15.7% with targeted vitamin D management and 18.4% with usual care (hazard ratio 0.85, 95% CI 0.58 to 1.24; P=0.40).

Key takeaways

At baseline, 87% of participants had a 25-hydroxyvitamin D level of 40 ng/mL or lower.
The primary composite outcome and the individual outcomes of death, heart-failure hospitalization, and stroke were not significantly different.
A lower recurrent-MI rate was a secondary finding and should not override the nonsignificant primary result.

Why this matters on shift

The trial cautions against presenting targeted vitamin D supplementation as a proven strategy for reducing major cardiovascular events after myocardial infarction.

Bedside takeaway

Present vitamin D as prescribed supplementation, not as a replacement for established post-MI secondary prevention.

Nursing implications

Reinforce the prescribed secondary-prevention plan and avoid implying that vitamin D replaces therapies with established post-MI benefit.

Limitations & cautions

Abstract-only summary. The trial included 630 participants, 78.1% were men, the primary confidence interval included benefit and no benefit, and individual secondary outcomes were not the primary endpoint.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

European heart journal (PubMed). Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

One in four laboratory-defined AKI cases went undocumented on medicine wards

Low-risk birth-center births showed no higher neonatal mortality in a 10-year analysis

Targeted vitamin D did not significantly reduce major cardiovascular events after MI